Welcome to our dedicated page for Lineage Cell Therapeutics SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lineage Cell Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lineage Cell Therapeutics's regulatory disclosures and financial reporting.
Lineage Cell Therapeutics, Inc. is asking shareholders to vote at its June 10, 2026 annual meeting on electing seven directors, ratifying Baker Tilly US, LLP as auditor for 2026, and approving on an advisory basis 2025 executive pay. Shareholders of record as of April 20, 2026, when 249,298,295 common shares were outstanding, may vote by internet, phone, mail, or in person. The proxy also details board structure, director independence, committee responsibilities, sustainability initiatives, and 2025 compensation, including a performance-based bonus program and stock option grants for directors and executives.
Lineage Cell Therapeutics President and CEO Brian M. Culley reported an open-market purchase of 15,000 common shares at a weighted average price of $1.625 per share. Following these purchases, he directly holds 255,516 common shares.
Lineage Cell Therapeutics, Inc. is registering up to $100,000,000 of securities to sell from time to time under a shelf registration. The registration covers common shares, preferred shares, debt securities and warrants, and securities issuable upon conversion or exercise, with specific terms to be provided in prospectus supplements.
The company states its common shares trade on the NYSE American and the TASE under the symbol LCTX, and reports a last NYSE American sale price of $1.77 per share on March 9, 2026. Proceeds treatment and offering mechanics will be described in each prospectus supplement; the prospectus permits sales directly, through agents, or via underwriters and contemplates at-the-market and other distribution methods.
Lineage Cell Therapeutics, Inc. filed a new prospectus supplement to support an at-the-market offering of its common shares with an aggregate offering price of up to $60,000,000 through or to B. Riley Securities, Inc. This program is under an existing Form S-3 shelf registration and sales agreement framework and excludes $22,583,663.82 in common shares already sold under prior prospectus supplements.
Ligand Pharmaceuticals, Inc. amends its prospectus supplement to increase the aggregate amount of common shares it may sell under its at-the-market sales agreement with B. Riley Securities, Inc. to $60,000,000. The supplement states this raises the ceiling for sales under the Sales Agreement dated March 22, 2024.
The supplement notes $22,583,663.82 in aggregate gross sales have been sold under the prior supplements and base prospectus to date. The filing also discloses the last reported NYSE American sale price of the common shares was $1.77 per share on March 9, 2026. The offering is subject to the Base Prospectus, prior supplements and the risk factors already disclosed.
Lineage Cell Therapeutics reported that its President and CEO, Brian M. Culley, received a grant of stock options covering 3,250,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the terms, one quarter of these options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments thereafter, contingent on continued employment. Following this award, Culley holds 3,250,000 stock options directly.
Lineage Cell Therapeutics, Inc. reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options on March 5, 2026. These options carry a stated exercise price of $0.0000 per share, reflecting a compensatory award rather than an open-market purchase.
According to the terms, one quarter of the options will vest on March 5, 2027. The remaining three quarters will then vest in 36 equal monthly installments, contingent on the completion of each month of continuous employment. Following this grant, Howe’s directly held option position from this award totals 1,050,000 options.
Samuel George A. III reported acquisition or exercise transactions in this Form 4 filing.
Lineage Cell Therapeutics, Inc. reported that its General Counsel and Secretary, Samuel George A. III, received a grant of 900,000 employee stock options on March 5, 2026. These options were awarded at no purchase price at grant as part of his compensation.
According to the vesting terms, one quarter of the options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments after that date, contingent on continuous employment each month.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell replacement therapies to treat serious conditions caused by loss or dysfunction of specific cell types, an approach it calls “Replace and Restore.” All programs are built on its proprietary AlloSCOPE manufacturing platform for scalable, off‑the‑shelf pluripotent cell-derived products.
The lead asset, OpRegen (RG6501), an allogeneic retinal pigment epithelial therapy for geographic atrophy secondary to dry age-related macular degeneration, is partnered worldwide with Roche and Genentech. Lineage received a $50.0 million upfront payment and a $5.0 million development milestone, and remains eligible for up to $615.0 million in additional milestones plus tiered double‑digit royalties.
Lineage’s wholly owned pipeline includes OPC1 for spinal cord injury, which has RMAT and Orphan Drug designations and is being evaluated in the DOSED clinical study using a novel delivery device, and ReSonance (ANP1) for hearing loss, supported by a collaboration with William Demant Invest funding up to $12 million in preclinical work. Additional earlier initiatives target Type 1 diabetes manufacturing scale (ILT1), a hypoimmune iPSC line (RND1), and photoreceptor replacement (PNC1). As of March 5, 2026, Lineage had 249,087,529 common shares outstanding.